Hi everyone,
Welcome to all our new subscribers who joined us this week! We're thrilled to have you as part of The Weekly Pill community. Your readership means the world to us. If you could kindly share this newsletter with your friends or coworkers, we would greatly appreciate your support! This resource holds value for a wide range of individuals, including venture capitalists, students, professionals at all levels within pharmaceutical companies, and anyone with a curious mindset eager to learn. Your assistance in this endeavor is greatly appreciated.
I sincerely hope you enjoy reading our newsletter and that it adds value to your understanding of the biotech world. Wishing each of you a blessed week ahead, and I look forward to connecting with you all again next week for another update.
If you really enjoy what we're doing here, consider becoming a paid subscriber to encourage us and gain access to the paid section, which includes insights on upcoming catalysts next week, the most shorted biotech stocks, earnings, market comments, notes and M&A comments. Now let’s dive into last week recap!
Table of contents
How the market performed this week
Licenses / Partnerships
Clinical trials
Financing
RIF
Disease of the week
What I’ve read this week
Paid Content Section
Upcoming Catalysts Next Week
Reminders
Biotech Valuation
Most Shorted Biotech Stock as of This Week
Market
Notes from analysts
Venture Capital Market
M&A
How the market performed this week
ETFs
Gene Therapy
RNA Therapy
Big Pharma
Gainers / Decliners this week in biotech
News of the week
Licenses/Partnerships
Johnson & Johnson (JNJ)
Symbol: JNJ
Event Phase: II
Drug: ARX788
Indication: Solid Tumors
Lead Indication: N
Molecule: Monoclonal Antibody
Target: HER2/neu or ErbB-2, Microtubules (Tubulin)
LOA: 11%
Partner Companies: Zhejiang Medicine Co., Ltd. (600216)
Source Link: Business Wire
Johnson & Johnson (JNJ)
Symbol: JNJ
Event Phase: Preclinical
Drug: ARX788
Indication: Gastric Cancer
Lead Indication: N
Molecule: Monoclonal Antibody
Target: HER2/neu or ErbB-2, Microtubules (Tubulin)
Partner Companies: Zhejiang Medicine Co., Ltd. (600216)
Source Link: Business Wire
Johnson & Johnson (JNJ)
Symbol: JNJ
Event Phase: II
Drug: ARX788
Indication: HER2+ Breast Cancer
Lead Indication: N
Molecule: Monoclonal Antibody
Target: HER2/neu or ErbB-2, Microtubules (Tubulin)
LOA: 11%
Partner Companies: Zhejiang Medicine Co., Ltd. (600216)
Source Link: Business Wire
Johnson & Johnson (JNJ)
Symbol: JNJ
Event Phase: II
Drug: ARX517
Indication: Prostate Cancer
Lead Indication: N
Molecule: Monoclonal Antibody
Target: Prostate-specific Membrane Antigen (PSMA)/Folate hydrolase (FOLH1)
LOA: 11%
Source Link: Business Wire
Johnson & Johnson (JNJ)
Symbol: JNJ
Event Phase: I
Drug: ARX305
Indication: Cancer
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: Cluster of Differentiation 70 (CD70)
LOA: 5%
Partner Companies: Zhejiang Medicine Co., Ltd. (600216)
Source Link: Business Wire
Johnson & Johnson (JNJ)
Symbol: JNJ
Event Phase: Preclinical
Drug: ARX102
Indication: Cancer
Lead Indication: N
Molecule: Small Molecule
Target: IL-2 (Interleukin-2)
Partner Companies: Sino Biopharmaceutical Limited (1177)
Source Link: Business Wire
Johnson & Johnson (JNJ)
Symbol: JNJ
Event Phase: Preclinical
Drug: ReCODE/EuCODE Program (Ambrx/Beigene)
Indication: Undisclosed
Lead Indication: Y
Molecule: Protein
Target: Unknown
Partner Companies: BeiGene, Ltd. (BGNE)
Source Link: Business Wire
Tonix Pharmaceuticals Holding Corp. (TNXP)
Symbol: TNXP
Event Phase: III
Drug: Tonmya
Indication: Fibromyalgia
Lead Indication: Y
Molecule: Small Molecule
Target: Alpha 2 Adrenergic Receptor, Serotonin 5-HT2A receptor
LOA: 39%
Source Link: Globe Newswire
Peak Bio Co., Ltd. (PKBO)
Symbol: PKBO
Event Phase: I
Drug: PHP-303
Indication: Alpha-1 Antitrypsin Deficiency (A1AD or AATD)
Lead Indication: N
Molecule: Not Specified
Target: Human Neutrophil elastase (hNE)
LOA: 15%
Source Link: Globe Newswire
Peak Bio Co., Ltd. (PKBO)
Symbol: PKBO
Event Phase: Preclinical
Drug: PHP-303
Indication: Acute Respiratory Failure, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS)
Lead Indication: N
Molecule: Not Specified
Target: Human Neutrophil elastase (hNE)
Source Link: Globe Newswire
Peak Bio Co., Ltd. (PKBO)
Symbol: PKBO
Event Phase: Preclinical
Drug: Trop2 PH1 ADC (Peak Bio)
Indication: Solid Tumors
Lead Indication: N
Molecule: Monoclonal Antibody
Target: Trop-2
Source Link: Globe Newswire
AbbVie Inc. (ABBV)
Symbol: ABBV
Event Phase: I
Drug: ABBV-303
Indication: Solid Tumors
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: Immune System, MET proto-oncogene, receptor tyrosine kinase, Natural Killer Cells (NK Cells)
LOA: 5%
Partner Companies: Dragonfly Therapeutics, Inc.
Source Link: PR Newswire
BridgeBio Pharma, Inc. (BBIO)
Symbol: BBIO
Event Phase: NDA/BLA
Drug: Acoramidis
Indication: Transthyretin Amyloid Cardiomyopathy (ATTR-CM, Wild Type Or Hereditary)
Lead Indication: N
Molecule: Small Molecule
Target: Transthyretin (TTR)
LOA: 88%
Partner Companies: AstraZeneca PLC (AZN), Bayer AG (BAYN)
Source Link: Globe Newswire
Clinical trials (LOA=likelihood of approval)
Gabather
Symbol: GABA
Event Phase: Development Outside U.S.
Drug: GT-002 (Gabather)
Indication: Psychiatric Disorder or Disease
Lead Indication: N
Molecule: Small Molecule
Target: GABA-A Receptor
LOA: N/A
Partner Companies: N/A
Source Link: Gabather Reports Initial Positive Results...
Ultimovacs ASA
Symbol: ULTIMO
Event Phase: II
Drug: UV-1
Indication: Melanoma
Lead Indication: N
Molecule: Vaccine
Target: Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Telomerase
LOA: 11%
Partner Companies: N/A
Source Link: Ultimovacs Announces Topline Results...
GSK plc
Symbol: GSK
Event Phase: Approved
Drug: Blenrep
Indication: Multiple Myeloma (MM)
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: B-cell maturation antigen (BCMA), Immune System, Tumor Cells
LOA: 100%
Partner Companies: Pfizer Inc. (PFE)
Source Link: GSK Announces Positive Results...
Mind Medicine, Inc.
Symbol: MNMD
Event Phase: II
Drug: MM-120
Indication: Generalized Anxiety Disorder (GAD)
Lead Indication: Y
Molecule: Not Specified
Target: Serotonin 5-HT2A receptor
LOA: 19%
Partner Companies: Liechti Laboratory
Source Link: Business Wire
Alligator Bioscience AB
Symbol: ATORX
Event Phase: I
Drug: ALG.APV-527
Indication: Solid Tumors
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: 5T4 tumor antigen, Cluster of Differentiation 137 (CD 137), Immune System
LOA: 5%
Partner Companies: Aptevo Therapeutics Inc. (APVO)
Source Link: AccessWire
Mustang Bio Inc.
Symbol: MBIO
Event Phase: I
Drug: MB-101
Indication: Brain Cancer (Malignant Glioma; AA and glioblastoma (GBM))
Lead Indication: Y
Molecule: Cellular
Target: Autologous Chimeric Antigen Receptor T-cells (CAR-T), IL-13 Receptor (IL-13R), Immune System, Stem Cells/Other Cell Therapies
LOA: 5%
Partner Companies: City of Hope
Source Link: GlobeNewswire
AlzeCure Pharma AB
Symbol: ALZCUR
Event Phase: Development Outside U.S.
Drug: ACD-856
Indication: Alzheimer's Disease (AD)
Lead Indication: N
Molecule: Small Molecule
Target: Trk (Tropomyosin Receptor Kinase) Receptors
LOA: N/A
Partner Companies: N/A
Source Link: AlzeCure Presents New Preclinical Data...
Redx Pharma Plc
Symbol: REDX
Event Phase: Preclinical
Drug: RXC-007
Indication: Pancreatic Cancer
Lead Indication: N
Molecule: Small Molecule
Target: ROCK (Rho-associated protein kinase)
LOA: N/A
Partner Companies: N/A
Source Link: Abstracts Online
Cognition Therapeutics, Inc.
Symbol: CGTX
Event Phase: II
Drug: Elayta
Indication: Alzheimer's Disease (AD)
Lead Indication: Y
Molecule: Small Molecule
Target: Amyloid Beta/Amyloid Plaques
LOA: 13%
Partner Companies: N/A
Source Link: GlobeNewswire
Gilead Sciences, Inc.
Symbol: GILD
Event Phase: Approved
Drug: Biktarvy
Indication: HIV / AIDS Treatment
Lead Indication: Y
Molecule: Small Molecule
Target: HIV Integrase
LOA: 100%
Partner Companies: Royalty Pharma plc (RPRX)
Source Link: Business Wire
Biomea Fusion, Inc.
Symbol: BMEA
Event Phase: II
Drug: BMF-219
Indication: Diabetes Mellitus, Type II
Lead Indication: N
Molecule: Small Molecule
Target: Menin
LOA: 17%
Partner Companies: N/A
Source Link: LiebertPub
Bristol Myers Squibb Company
Symbol: BMY
Event Phase: II
Drug: BMS-986442
Indication: Solid Tumors
Lead Indication: N
Molecule: Monoclonal Antibody
Target: Immune System, TIGIT
LOA: 11%
Partner Companies: Agenus Inc. (AGEN)
Source Link: Business Wire
Medigene AG
Symbol: MDG1
Event Phase: Preclinical
Drug: MDG-1015
Indication: Solid Tumors
Lead Indication: N
Molecule: Cellular
Target: NY-ESO-1 (Cancer-testis antigen)
LOA: N/A
Partner Companies: N/A
Source Link: GlobeNewswire
Genprex, Inc.
Symbol: GNPX
Event Phase: II
Drug: Reqorsa
Indication: Small Cell Lung Cancer (SCLC)
Lead Indication: N
Molecule: Other Nucleic Acid
Target: Apoptosis (Cell Death), Immune System
LOA: 11%
Partner Companies: University of Texas MD Anderson Cancer Center
Source Link: Abstracts Online
Genprex, Inc.
Symbol: GNPX
Event Phase: Preclinical
Drug: NPRL2 Gene Therapy (Genprex)
Indication: Non-Small Cell Lung Cancer (NSCLC)
Lead Indication: N
Molecule: Non-Viral Gene Therapy
Target: Tumor Cells
LOA: N/A
Partner Companies: N/A
Source Link: PR Newswire
Rezolute, Inc.
Symbol: RZLT
Event Phase: III
Drug: RZ358
Indication: Congenital Hyperinsulinism (CHI)
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: Insulin Receptor
LOA: 59%
Partner Companies: XOMA Corporation (XOMA)
Source Link: GlobeNewswire
Agenus Inc.
Symbol: AGEN
Event Phase: Preclinical
Drug: MiNK-215
Indication: Colorectal Cancer (CRC)
Lead Indication: N
Molecule: Cellular
Target: Fibroblast Activation Protein (FAP), NKT Cells
LOA: N/A
Partner Companies: N/A
Source Link: GlobeNewswire
Gilead Sciences, Inc.
Symbol: GILD
Event Phase: Approved
Drug: Sunlenca
Indication: HIV / AIDS Treatment
Lead Indication: Y
Molecule: Small Molecule
Target: Viral Capsid
LOA: 100%
Partner Companies: N/A
Source Link: CROI Conference
Gilead Sciences, Inc.
Symbol: GILD
Event Phase: II
Drug: GS-2872
Indication: HIV / AIDS Treatment
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: Human Immunodeficiency Virus (HIV)
LOA: 23%
Partner Companies: N/A
Source Link: CROI Conference
Edgewise Therapeutics, Inc.
Symbol: EWTX
Event Phase: II
Drug: EDG-5506
Indication: Becker Muscular Dystrophy (BMD)
Lead Indication: Y
Molecule: Small Molecule
Target: Myosin
LOA: 25%
Partner Companies: N/A
Source Link: MDA Conference
Biogen, Inc.
Symbol: BIIB
Event Phase: Approved
Drug: Spinraza
Indication: Spinal Muscular Atrophy
Lead Indication: Y
Molecule: Antisense
Target: Survival of Motor Neuron (SMN) Protein
LOA: 100%
Partner Companies: Ionis Pharmaceuticals, Inc. (IONS), Royalty Pharma plc (RPRX)
Source Link: GlobeNewswire
Rezolute, Inc.
Symbol: RZLT
Event Phase: III
Drug: RZ358
Indication: Congenital Hyperinsulinism (CHI)
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: Insulin Receptor
LOA: 59%
Partner Companies: XOMA Corporation (XOMA)
Source Link: GlobeNewswire
Agenus Inc.
Symbol: AGEN
Event Phase: Preclinical
Drug: MiNK-215
Indication: Colorectal Cancer (CRC)
Lead Indication: N
Molecule: Cellular
Target: Fibroblast Activation Protein (FAP), NKT Cells
LOA: N/A
Partner Companies: N/A
Source Link: GlobeNewswire
Gilead Sciences, Inc.
Symbol: GILD
Event Phase: Approved
Drug: Sunlenca
Indication: HIV / AIDS Treatment
Lead Indication: Y
Molecule: Small Molecule
Target: Viral Capsid
LOA: 100%
Partner Companies: N/A
Source Link: CROI Conference
Gilead Sciences, Inc.
Symbol: GILD
Event Phase: II
Drug: GS-2872
Indication: HIV / AIDS Treatment
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: Human Immunodeficiency Virus (HIV)
LOA: 23%
Partner Companies: N/A
Source Link: CROI Conference
Edgewise Therapeutics, Inc.
Symbol: EWTX
Event Phase: II
Drug: EDG-5506
Indication: Becker Muscular Dystrophy (BMD)
Lead Indication: Y
Molecule: Small Molecule
Target: Myosin
LOA: 25%
Partner Companies: N/A
Source Link: MDA Conference
Biogen, Inc.
Symbol: BIIB
Event Phase: Approved
Drug: Spinraza
Indication: Spinal Muscular Atrophy
Lead Indication: Y
Molecule: Antisense
Target: Survival of Motor Neuron (SMN) Protein
LOA: 100%
Partner Companies: Ionis Pharmaceuticals, Inc. (IONS), Royalty Pharma plc (RPRX)
Source Link: GlobeNewswire
MAIA Biotechnology, Inc.
Symbol: MAIA
Event Phase: II
Drug: THIO
Indication: Non-Small Cell Lung Cancer (NSCLC)
Lead Indication: Y
Molecule: Small Molecule
Target: DNA synthesis, Telomeres
LOA: 15%
Partner Companies: N/A
Source Link: Business Wire
Gilead Sciences, Inc.
Symbol: GILD
Event Phase: III
Drug: Bictegravir/Lenacapavir
Indication: HIV / AIDS Treatment
Lead Indication: Y
Molecule: Small Molecule
Target: Unknown
LOA: 61%
Partner Companies: N/A
Gilead Sciences, Inc.
Symbol: GILD
Event Phase: II
Drug: GS-5423
Indication: HIV / AIDS Treatment
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: Human Immunodeficiency Virus (HIV)
LOA: 23%
Partner Companies: N/A
Source Link: CROI Conference
Merck & Co., Inc.
Symbol: MRK
Event Phase: II
Drug: MK-8591D
Indication: HIV / AIDS Treatment
Lead Indication: Y
Molecule: Small Molecule
Target: Reverse Transcriptase, Viral Capsid
LOA: 26%
Partner Companies: Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc.
Symbol: GILD
Event Phase: I
Drug: GS-1720
Indication: HIV / AIDS Treatment
Lead Indication: N
Molecule: Small Molecule
Target: HIV Integrase
LOA: 13%
Partner Companies: N/A
Source Link: Business Wire
Regenxbio Inc.
Symbol: RGNX
Event Phase: II
Drug: RGX-202 (Regenxbio)
Indication: Duchenne Muscular Dystrophy (DMD)
Lead Indication: N
Molecule: Viral Gene Therapy
Target: Dystrophin gene (DMD)
LOA: 25%
Partner Companies: N/A
Source Link: MDA Conference
Dyne Therapeutics
Symbol: DYN
Event Phase: Preclinical
Drug: DYNE-101
Indication: Myotonic Muscular Dystrophy
Lead Indication: Y
Molecule: Antisense
Target: Myotonic dystrophy protein kinase (DMPK) gene
LOA: N/A
Partner Companies: N/A
Source Link: MDA Conference
GSK plc
Symbol: GSK
Event Phase: Approved
Drug: Cabenuva
Indication: HIV / AIDS Treatment
Lead Indication: Y
Molecule: Small Molecule
Target: HIV Integrase
LOA: 100%
Partner Companies: Johnson & Johnson (JNJ)
Source Link: Business Wire
Dyne Therapeutics
Symbol: DYN
Event Phase: II
Drug: DYNE-251
Indication: Duchenne Muscular Dystrophy (DMD)
Lead Indication: Y
Molecule: Antisense
Target: Dystrophin gene (DMD)
LOA: 25%
Partner Companies: N/A
Source Link: MDA Conference
Vaxxinity, Inc.
Symbol: VAXX
Event Phase: I
Drug: UB-312
Indication: Parkinson's Disease (PD)
Lead Indication: Y
Molecule: Peptide
Target: Alpha-synuclein
LOA: 6%
Partner Companies: N/A
Source Link: CSlide
Dynavax Technologies Corporation
Symbol: DVAX
Event Phase: Approved
Drug: Heplisav-B
Indication: Hepatitis B Prevention (Vaccines, Antiviral)
Lead Indication: Y
Molecule: Vaccine
Target: Immune System, Toll-like receptor 9 (TLR9)
LOA: 100%
Partner Companies: Bavarian Nordic A/S (BAVA), Pfizer Inc. (PFE)
Source Link: GlobeNewswire
Ryvu Therapeutics
Symbol: RVU
Event Phase: Preclinical
Drug: SEL24
Indication: Myelofibrosis (MF)
Lead Indication: N
Molecule: Small Molecule
Target: FMS-like tyrosine kinase 3 (FLT-3), PIM Kinase Family
LOA: N/A
Partner Companies: The Menarini Group
Source Link: PR Newswire
Redx Pharma Plc
Symbol: REDX
Event Phase: II
Drug: RXC-004
Indication: Solid Tumors
Lead Indication: Y
Molecule: Small Molecule
Target: WNT Signaling Pathway
LOA: 11%
Partner Companies: N/A
Source Link: Redx Pharma Plc
Opko Health
Symbol: OPK
Event Phase: I
Drug: SAR441236
Indication: HIV Prevention
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: gp120, Human immunodeficiency virus type 1 (HIV-1)
LOA: 13%
Partner Companies: National Institutes of Health, Sanofi (SNY)
Source Link: GlobeNewswire
Nicox S.A.
Symbol: COX
Event Phase: III
Drug: NCX 470
Indication: Glaucoma / Ocular Hypertension (Ophthalmology)
Lead Indication: Y
Molecule: Small Molecule
Target: Prostaglandin F receptor (FP)/PGF2 alpha receptor
LOA: 54%
Partner Companies: Kowa Company, Ltd., Ocumension Therapeutics (1477)
Source Link: GlobeNewswire
Regenxbio Inc.
Symbol: RGNX
Event Phase: II
Drug: RGX-202 (Regenxbio)
Indication: Duchenne Muscular Dystrophy (DMD)
Lead Indication: N
Molecule: Viral Gene Therapy
Target: Dystrophin gene (DMD)
LOA: 25%
Partner Companies: N/A
Source Link: PR Newswire
Roche Holding AG
Symbol: RHHBY
Event Phase: II
Drug: Zilebesiran
Indication: Hypertension (Systemic)
Lead Indication: Y
Molecule: siRNA/RNAi
Target: Angiotensins (I-IV)
LOA: 10%
Partner Companies: Alnylam Pharmaceuticals Inc. (ALNY)
Source Link: Business Wire
Novo Nordisk A/S
Symbol: NVO
Event Phase: III
Drug: Ozempic
Indication: Diabetic Nephropathy
Lead Indication: N
Molecule: Peptide
Target: GLP-1 Receptor
LOA: 57%
Partner Companies: N/A
Source Link: GlobeNewswire
Novo Nordisk A/S
Symbol: NVO
Event Phase: III
Drug: Ozempic
Indication: Non-Alcoholic Steatohepatitis (NASH)
Lead Indication: N
Molecule: Peptide
Target: GLP-1 Receptor
LOA: 60%
Partner Companies: N/A
Source Link: GlobeNewswire
BioInvent International AB
Symbol: BINV
Event Phase: II
Drug: BI-1206
Indication: Non-Hodgkin's Lymphoma (NHL)
Lead Indication: N
Molecule: Monoclonal Antibody
Target: Fc receptors, Immune System
LOA: 11%
Partner Companies: Cancer Research Technology Ltd., Cancer Research UK, CASI Pharmaceuticals, Inc. (CASI)
Source Link: PR Newswire
Apogee Therapeutics, LLC
Symbol: APGE
Event Phase: I
Drug: APG777
Indication: Atopic Dermatitis (Eczema)
Lead Indication: N
Molecule: Monoclonal Antibody
Target: IL-13 (Interleukin-13)
LOA: 10%
Partner Companies: Paragon Therapeutics, Inc.
Source Link: GlobeNewswire
Tonix Pharmaceuticals Holding Corp.
Symbol: TNXP
Event Phase: I
Drug: TNX-1500
Indication: Kidney Transplant Rejection
Lead Indication: N
Molecule: Monoclonal Antibody
Target: Cluster of Differentiation 154 (CD154) / CD40 Ligand (CD40L) / gp39
LOA: 11%
Partner Companies: N/A
Source Link: GlobeNewswire
Monopar Therapeutics LLC
Symbol: MNPR
Event Phase: Preclinical
Drug: MNPR-101
Indication: Solid Tumors
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: Urokinase (uPA)/Urokinase Receptor (uPAR)
LOA: N/A
Partner Companies: Cancer Research UK
Source Link: GlobeNewswire
GenSight Biologics S.A.
Symbol: SIGHT
Event Phase: III
Drug: Lumevoq
Indication: Leber's Hereditary Optic Neuropathy (LHON) (Ophthalmology)
Lead Indication: Y
Molecule: Viral Gene Therapy
Target: Mitochondrial Electron Transport Chain, NADPH: Quinone Oxidoreductase-1 (NQO1)
LOA: 53%
Partner Companies: N/A
Source Link: Business Wire
Merus N.V.
Symbol: MRUS
Event Phase: II
Drug: Zenocutuzumab
Indication: Solid Tumors
Lead Indication: N
Molecule: Monoclonal Antibody
Target: ErbB3/HER3, HER2/neu or ErbB-2
LOA: 17%
Partner Companies: N/A
Source Link: GlobeNewswire
Cantargia AB
Symbol: CANTA
Event Phase: II
Drug: CAN04
Indication: Pancreatic Cancer
Lead Indication: Y
Molecule: Monoclonal Antibody
Target: IL-1 Receptor (IL-1R)
LOA: 11%
Partner Companies: Cellerant Therapeutics, Inc.
Source Link: Cantargia AB
Verastem, Inc.
Symbol: VSTM
Event Phase: III
Drug: VS-6766
Indication: Ovarian Cancer
Lead Indication: N
Molecule: Small Molecule
Target: Mitogen-activated ERK kinase (MEK, MAPKK, MAP2K), Raf kinase
LOA: 44%
Partner Companies: Chugai Pharmaceutical Co., Ltd. (4519)
Source Link: Verastem, Inc.
CervoMed, Inc.
Symbol: CRVO
Event Phase: II
Drug: Neflamapimod
Indication: Lewy Body Dementia (LBD)
Lead Indication: N
Molecule: Small Molecule
Target: p38 MAP kinase (MAPK)
LOA: 15%
Partner Companies: Vertex Pharmaceuticals Incorporated (VRTX)
Source Link: GlobeNewswire
Lyell Immunopharma Inc.
Symbol: LYEL
Event Phase: Preclinical
Drug: LYL119
Indication: Solid Tumors
Lead Indication: N
Molecule: Cellular
Target: Immune System, Tyrosine Kinases
LOA: N/A
Partner Companies: N/A
Source Link: GlobeNewswire
CervoMed, Inc.
Symbol: CRVO
Event Phase: II
Drug: Neflamapimod
Indication: Lewy Body Dementia (LBD)
Lead Indication: N
Molecule: Small Molecule
Target: p38 MAP kinase (MAPK)
LOA: 15%
Partner Companies: Vertex Pharmaceuticals Incorporated (VRTX)
Source Link: GlobeNewswire
Gain Therapeutics, Inc.
Symbol: GANX
Event Phase: Development Outside U.S.
Drug: GT-02287
Indication: Parkinson's Disease (PD)
Lead Indication: N
Molecule: Small Molecule
Target: GBA2 (extralysosomal glucocerebrosidase)
LOA: N/A
Partner Companies: N/A
Source Link: GlobeNewswire
ORIC Pharmaceuticals, Inc.
Symbol: ORIC
Event Phase: I
Drug: ORIC-944
Indication: Prostate Cancer
Lead Indication: Y
Molecule: Small Molecule
Target: EZH1/2
LOA: 5%
Partner Companies: Bristol Myers Squibb Company (BMY)
Source Link: GlobeNewswire
ORIC Pharmaceuticals, Inc.
Symbol: ORIC
Event Phase: Preclinical
Drug: ORIC-613
Indication: Breast Cancer
Lead Indication: N
Molecule: Small Molecule
Target: Polo-Like Kinase 4 (PLK4)
LOA: N/A
Partner Companies: N/A
Source Link: GlobeNewswire
INmune Bio, Inc.
Symbol: INMB
Event Phase: II
Drug: XPro-1595
Indication: Alzheimer's Disease (AD)
Lead Indication: Y
Molecule: Protein
Target: Tumor Necrosis Factor-alpha (TNF-alpha)
LOA: 12%
Partner Companies: FPRT Bio, Xencor, Inc. (XNCR)
Source Link: GlobeNewswire
Creative Medical Technology Holdings, Inc.
Symbol: CELZ
Event Phase: Preclinical
Drug: ImmCelz
Indication: Transplant Rejection
Lead Indication: N
Molecule: Small Molecule
Target: Immune System, Stem Cells/Other Cell Therapies
LOA: N/A
Partner Companies: N/A
Source Link: BusinessWire
Immunocore, Ltd.
Symbol: IMCR
Event Phase: I
Drug: IMC-M113V
Indication: HIV / AIDS Treatment
Lead Indication: Y
Molecule: Protein
Target: Cluster of Differentiation 3 (CD3), Human Immunodeficiency Virus (HIV), Immune System, Major Histocompatibility Complex (MHC), T lymphocytes
LOA: 13%
Partner Companies: N/A
Source Link: GlobeNewswire
Financing events
Akero Therapeutics (NAS: AKRO)
Description: Clinical-stage biotechnology company focusing on transformative treatments for metabolic diseases.
Verticals: Life Sciences
Deal Date: 04-mars-2024
Deal Type: Public Investment 2nd Offering
Deal Synopsis: Filed for a second public offering on Nasdaq, selling 11,000,000 shares at $29 each, expecting $319 million.
Investors: Not Applicable
Deal Size: $319.00 million
Alumis
Description: Developer of precision medicines for autoimmune diseases.
Verticals: Life Sciences, LOHAS & Wellness
Deal Date: 06-mars-2024
Deal Type: Later Stage VC
Deal Synopsis: Raised $259 million of Series C venture funding, led by Foresite Capital and Samsara BioCapital.
Investors: Foresite Capital, Samsara BioCapital, and others
Deal Size: $259.00 million
Apogee Therapeutics (NAS: APGE)
Description: Biotechnology company developing biologics for dermatitis and pulmonary diseases.
Verticals: Life Sciences
Deal Date: 05-mars-2024
Deal Type: Public Investment 2nd Offering
Deal Synopsis: Filed for a second public offering, intending to sell 6,000,000 shares.
Investors: Not Applicable
Deal Size: Not specified
Arcutis Biotherapeutics (NAS: ARQT)
Description: Medical dermatology company focusing on immune-mediated dermatological diseases.
Verticals: Life Sciences
Deal Date: 04-mars-2024
Deal Type: Public Investment 2nd Offering
Deal Synopsis: Raised $150 million in second public offering, selling 15,789,474 shares at $9.50 each.
Investors: Not Applicable
Deal Size: $150.00 million
BioAffinity Technologies (NAS: BIAF)
Description: Developing noninvasive diagnostic tests and cancer therapeutics.
Verticals: Life Sciences, Oncology
Deal Date: 06-mars-2024
Deal Type: PIPE
Deal Synopsis: In talks to receive $2.5 million of development capital from undisclosed investors.
Investors: Not Applicable
Deal Size: $2.50 million
Bone Biologics (NAS: BBLG)
Description: Healthcare solutions provider developing therapeutics for bone regeneration.
Verticals: Life Sciences
Deal Date: 06-mars-2024
Deal Type: Public Investment 2nd Offering
Deal Synopsis: Raised $304,640 in second public offering, selling 119,000 shares at $2.56 each.
Investors: Not Applicable
Deal Size: $0.30 million
BridgeBio Pharma (NAS: BBIO)
Description: Identifying transformative medicines for genetic diseases and cancers.
Verticals: Life Sciences, Oncology
Deal Date: 04-mars-2024
Deal Type: Public Investment 2nd Offering
Deal Synopsis: Raised $250 million in second public offering, selling 8,620,690 shares at $29 each.
Investors: Not Applicable
Deal Size: $250.00 million
Cellcolabs
Description: Developer of cell therapies aimed at curing multiple diseases.
Verticals: HealthTech, Life Sciences
Deal Date: 05-mars-2024
Deal Type: Early Stage VC
Deal Synopsis: Raised $8.7 million in venture funding from Norrsken VC, Fredrik Österberg, and others.
Investors: Norrsken VC, Fredrik Österberg, Jens von Bahr, Jonas Nordlander, and others
Deal Size: $8.70 million
Celldex Therapeutics (NAS: CLDX)
Description: Biopharmaceutical company focused on immunotherapy technologies.
Verticals: Life Sciences, Oncology
Deal Date: 04-mars-2024
Deal Type: Public Investment 2nd Offering
Deal Synopsis: Raised $400.44 million in second public offering, selling 8,520,000 shares at $47 each.
Investors: Not Applicable
Deal Size: $400.44 million
First Wave BioPharma (NAS: FWBI)
Description: Clinical-stage biopharmaceutical company specializing in targeted therapies for gastrointestinal diseases.
Verticals: Life Sciences, Manufacturing
Deal Date: 04-mars-2024
Deal Type: Public Investment 2nd Offering
Deal Synopsis: Raised $1.317 million in second public offering, selling 173,100 shares at $7.61 each.
Investors: Not Applicable
Deal Size: $1.32 million
ME Therapeutics (CNQ: METX)
Description: Biotechnology company focused on advancing therapeutics for Parkinson's disease and other neurological disorders.
Verticals: Life Sciences
Deal Date: 04-mars-2024
Deal Type: PIPE
Deal Synopsis: In talks to receive $5 million of development capital from undisclosed investors.
Investors: Not Applicable
Deal Size: $5.00 million
Orchard Therapeutics (NAS: ORTX)
Description: Biotechnology company focused on gene therapies for rare diseases.
Verticals: Life Sciences
Deal Date: 06-mars-2024
Deal Type: Public Investment 2nd Offering
Deal Synopsis: Raised $72 million in second public offering, selling 10,000,000 shares at $7.20 each.
Investors: Not Applicable
Deal Size: $72.00 million
Repare Therapeutics (NAS: RPTX)
Description: Precision oncology company developing novel therapeutics for genomically-defined cancers.
Verticals: Life Sciences, Oncology
Deal Date: 04-mars-2024
Deal Type: Public Investment 2nd Offering
Deal Synopsis: Raised $40 million in second public offering, selling 5,714,285 shares at $7 each.
Investors: Not Applicable
Deal Size: $40.00 million
Reduction in force (RIF)
March 5 - Meissa Vaccines: RSV-focused Meissa is halting development activities and laying off an undisclosed number of workers given the current fundraising environment, the company told Fierce Biotech. Story
March 5 - Sumitomo Pharma: Hundreds of layoffs last summer weren't enough to stem the tide, with the Japanese drugmaker letting go of 400 staffers this month. The cuts at Sumitomo Pharma America come amid a “severe business environment” and are part of an effort to boost organizational efficiency and streamline operations. Story
March 4 - Arrakis Therapeutics: The RNA-focused biotech is laying off 20% of staff, with 71 employees remaining after the cuts are implemented, an Arrakis spokesperson told Fierce Biotech.
Disease of the week
Trimethylaminuria, also known as "fish odor syndrome" or "TMAU," is a metabolic disorder characterized by a strong body odor that resembles the smell of rotting fish. This condition occurs due to the body's inability to break down a compound called trimethylamine (TMA), which is produced during the digestion of certain foods containing choline, trimethylamine oxide, and carnitine.
Here's a comprehensive overview of Trimethylaminuria:
Causes:
Genetic Mutation: Trimethylaminuria is primarily caused by mutations in the FMO3 gene, which provides instructions for making an enzyme called flavin-containing monooxygenase 3 (FMO3). This enzyme is responsible for converting TMA into its odorless form, trimethylamine N-oxide (TMAO).
Inefficient Enzyme Function: Mutations in the FMO3 gene result in a deficiency or inefficiency of the FMO3 enzyme, leading to the accumulation of TMA in the body, which is then released through sweat, urine, and breath.
Symptoms:
Strong Body Odor: Individuals with trimethylaminuria excrete a strong, unpleasant odor resembling fishy or rotten eggs.
Increased Body Odor after Ingesting Certain Foods: Symptoms worsen after consuming foods rich in choline, trimethylamine oxide, and carnitine, such as eggs, fish, and other seafood.
Psychological Effects: The persistent odor may lead to social anxiety, depression, and low self-esteem in affected individuals.
Diagnosis:
Odor Assessment: Diagnosis often begins with evaluating the characteristic fishy odor associated with the condition.
Genetic Testing: Genetic testing can confirm mutations in the FMO3 gene.
Urine or Blood Tests: Quantitative analysis of trimethylamine and its metabolites in urine or blood can help confirm the diagnosis.
Treatment:
Dietary Modifications: Limiting the intake of foods rich in precursors of trimethylamine, such as choline, trimethylamine oxide, and carnitine, can help reduce symptoms.
Supplements: Some individuals may benefit from supplements such as activated charcoal or copper chlorophyllin, which may help bind excess trimethylamine in the gut.
Low-Dose Antibiotics: In some cases, antibiotics like neomycin or metronidazole may be prescribed to reduce the production of trimethylamine by gut bacteria.
Symptomatic Management: Antiperspirants, body washes containing chlorophyll, and other odor-reducing products can help manage body odor.
Prognosis:
Trimethylaminuria is a chronic condition with no cure, but symptoms can be managed effectively with dietary modifications and other interventions. With proper management, individuals with trimethylaminuria can lead normal, fulfilling live
What I’ve read this week
*Click on the pic to read*
